SequelSEC

IB Acquisition Corp. IBAC

Services-Commercial Physical & Biological Research · CIK 0001998781 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-09-30
Operating income
-$748.91K
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

IB Acquisition Corp. (IBAC) reported net income of $3.42M for the fiscal year ended 2025-09-30. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from IB Acquisition Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

IB Acquisition Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-30
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$748.91K-$523.97K-$6.84K
Net income$3.42M$1.87M-$6.84K
Research & developmentUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax income$4.38M$2.50M-$6.84K
Income tax expense$965.64K$635.51KUnavailable
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$748.91K$523.97K$6.84K
Selling & marketingUnavailableUnavailableUnavailable

Balance

IB Acquisition Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-30
Cash & equivalents$428.70K$822.80K$52.55K
Total assets$17.13M$119.80M$52.55K
Current assets$1.24M$1.20M$52.55K
Total liabilities$1.83M$722.23K$57.99K
Current liabilities$1.83M$722.23K$57.99K
Total equity incl. NCI-$681.32K$1.11M-$5.43K
Temporary (mezzanine) equity$15.98M$117.97MUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable

Cash flow

IB Acquisition Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-30
Operating cash flow-$1.32M-$820.96K-$207
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow$107.84M-$115.58MUnavailable
Financing cash flow-$106.13M$117.17M$50.00K
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchases$106.13MUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

IB Acquisition Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-09-30
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratioUnavailable1.66x0.91x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rate22.0%25.4%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IBAC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-K · Filed 2025-12-29View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABSI BIAF BUDZ CBIH CRL FOXO INCY IQV ISPC MEDP MXCT NRC

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.